Royalty Pharma (MEX:RPRXN) Cash Flow for Dividends: MXN-7,087 Mil (TTM As of Mar. 2026)


MEX:RPRXN Royalty Pharma PLC MEX:RPRXN
72 GF Score
Price MXN775.06
GF Value MXN535.17
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Cash Flow for Dividends?

Royalty Pharma MEX:RPRXN 72 Cash Flow for Dividends is MXN-7,087 Mil as of Mar. 2026. GuruFocus rates MEX:RPRXN with a GF Score™ of 72/100 and a GF Value™ of MXN535.17. The stock has 10 warning signs investors should review.

Royalty Pharma's cash flow for dividends for the three months ended in Mar. 2026 was MXN-1,884 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-7,087 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Royalty Pharma's quarterly payment of dividends declined from Sep. 2025 (MXN-1,748 Mil) to Dec. 2025 (MXN-1,699 Mil) but then increased from Dec. 2025 (MXN-1,699 Mil) to Mar. 2026 (MXN-1,884 Mil).

Royalty Pharma's annual payment of dividends increased from Dec. 2023 (MXN-6,082 Mil) to Dec. 2024 (MXN-7,851 Mil) but then declined from Dec. 2024 (MXN-7,851 Mil) to Dec. 2025 (MXN-6,811 Mil).

Royalty Pharma Cash Flow for Dividends Related Terms

Royalty Pharma Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Cash Flow for Dividends Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only -5,850.27 -6,498.45 -6,082.33 -7,851.44 -6,810.71

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,950.83 -1,755.65 -1,748.42 -1,698.71 -1,884.24
MEX:RPRXN
72GF Score
Royalty Pharma PLC MEX:RPRXN
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-7,087 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of MXN-7,087 Mil mean?
Royalty Pharma (MEX:RPRXN) has a Cash Flow for Dividends of MXN-7,087 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Royalty Pharma and its competitors.
Is Royalty Pharma's Cash Flow for Dividends too high?
Royalty Pharma's current Cash Flow for Dividends is MXN-7,087 Mil. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Cash Flow for Dividends compare to BNTX and INSM?
Royalty Pharma's Cash Flow for Dividends of MXN-7,087 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Royalty Pharma and its competitors. Royalty Pharma's current Cash Flow for Dividends is MXN-7,087 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current Cash Flow for Dividends of MXN-7,087 Mil. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current Cash Flow for Dividends is MXN-7,087 Mil. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Cash Flow for Dividends is MXN-7,087 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.

Key valuation signals for MEX:RPRXN:

  • Cash Flow for Dividends: MXN-7,087 Mil
  • GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for MEX:RPRXN

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN775.06
Price
MXN535.17
GF Value